Gilead Sciences, Inc. (NASDAQ:GILD) to Issue Dividend Increase – $0.82 Per Share

Gilead Sciences, Inc. (NASDAQ:GILD) declared a quarterly dividend on Tuesday, February 10th. Stockholders of record on Friday, March 13th will be given a dividend of 0.82 per share by the biopharmaceutical company on Monday, March 30th. This represents a c) dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend is Friday, March 13th. This is a 3.8% increase from Gilead Sciences’s previous quarterly dividend of $0.79.

Gilead Sciences has raised its dividend payment by an average of 0.0%per year over the last three years and has increased its dividend annually for the last 10 consecutive years. Gilead Sciences has a payout ratio of 37.1% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Gilead Sciences to earn $8.11 per share next year, which means the company should continue to be able to cover its $3.16 annual dividend with an expected future payout ratio of 39.0%.

Gilead Sciences Stock Up 6.1%

Shares of GILD traded up $8.94 during trading hours on Wednesday, hitting $156.17. The stock had a trading volume of 7,754,233 shares, compared to its average volume of 7,844,875. The firm has a 50 day simple moving average of $128.39 and a 200-day simple moving average of $121.53. Gilead Sciences has a 1-year low of $93.37 and a 1-year high of $157.29. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The firm has a market capitalization of $193.76 billion, a P/E ratio of 24.21, a price-to-earnings-growth ratio of 0.80 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter in the previous year, the company posted $1.90 earnings per share. The company’s quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts predict that Gilead Sciences will post 7.95 EPS for the current fiscal year.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.